Logo image of RXST

RXSIGHT INC (RXST) Stock Fundamental Analysis

NASDAQ:RXST - US78349D1072 - Common Stock

9.035 USD
-0.24 (-2.64%)
Last: 8/25/2025, 10:19:55 AM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RXST. RXST was compared to 185 industry peers in the Health Care Equipment & Supplies industry. RXST scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, RXST is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

RXST had negative earnings in the past year.
RXST had a negative operating cash flow in the past year.
RXST had negative earnings in 4 of the past 5 years.
RXST had a negative operating cash flow in each of the past 5 years.
RXST Yearly Net Income VS EBIT VS OCF VS FCFRXST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

RXST's Return On Assets of -10.44% is in line compared to the rest of the industry. RXST outperforms 58.92% of its industry peers.
The Return On Equity of RXST (-11.60%) is better than 64.86% of its industry peers.
Industry RankSector Rank
ROA -10.44%
ROE -11.6%
ROIC N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
RXST Yearly ROA, ROE, ROICRXST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

RXST has a Gross Margin of 73.12%. This is amongst the best in the industry. RXST outperforms 84.86% of its industry peers.
RXST's Gross Margin has improved in the last couple of years.
RXST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
RXST Yearly Profit, Operating, Gross MarginsRXST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

More info and screens

6

2. Health

2.1 Basic Checks

RXST does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RXST has more shares outstanding
The number of shares outstanding for RXST has been increased compared to 5 years ago.
Compared to 1 year ago, RXST has an improved debt to assets ratio.
RXST Yearly Shares OutstandingRXST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RXST Yearly Total Debt VS Total AssetsRXST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 5.49 indicates that RXST is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.49, RXST belongs to the best of the industry, outperforming 80.54% of the companies in the same industry.
RXST has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
RXST has a Debt to Equity ratio of 0.00. This is in the better half of the industry: RXST outperforms 72.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.49
ROIC/WACCN/A
WACC8.9%
RXST Yearly LT Debt VS Equity VS FCFRXST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

RXST has a Current Ratio of 13.93. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
RXST's Current ratio of 13.93 is amongst the best of the industry. RXST outperforms 97.84% of its industry peers.
RXST has a Quick Ratio of 12.70. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 12.70, RXST belongs to the best of the industry, outperforming 97.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.93
Quick Ratio 12.7
RXST Yearly Current Assets VS Current LiabilitesRXST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.37% over the past year.
RXST shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.68%.
The Revenue has been growing by 128.63% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-81.25%
Revenue 1Y (TTM)27.68%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%-3.58%

3.2 Future

Based on estimates for the next years, RXST will show a small growth in Earnings Per Share. The EPS will grow by 6.61% on average per year.
Based on estimates for the next years, RXST will show a small growth in Revenue. The Revenue will grow by 2.50% on average per year.
EPS Next Y-74.25%
EPS Next 2Y-28.33%
EPS Next 3Y-14.72%
EPS Next 5Y6.61%
Revenue Next Year-10.36%
Revenue Next 2Y-2.2%
Revenue Next 3Y2.02%
Revenue Next 5Y2.5%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
RXST Yearly Revenue VS EstimatesRXST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
RXST Yearly EPS VS EstimatesRXST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RXST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXST Price Earnings VS Forward Price EarningsRXST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXST Per share dataRXST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

RXST's earnings are expected to decrease with -14.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.33%
EPS Next 3Y-14.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RXST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RXSIGHT INC

NASDAQ:RXST (8/25/2025, 10:19:55 AM)

9.035

-0.24 (-2.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-07 2025-11-07/amc
Inst Owners98.06%
Inst Owner Change4.24%
Ins Owners5.51%
Ins Owner Change9.73%
Market Cap369.71M
Analysts52.5
Price Target9.18 (1.6%)
Short Float %16.31%
Short Ratio4.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.73%
Min EPS beat(2)-16.68%
Max EPS beat(2)9.22%
EPS beat(4)3
Avg EPS beat(4)9.97%
Min EPS beat(4)-16.68%
Max EPS beat(4)36.3%
EPS beat(8)7
Avg EPS beat(8)17.13%
EPS beat(12)11
Avg EPS beat(12)18.4%
EPS beat(16)14
Avg EPS beat(16)15.43%
Revenue beat(2)0
Avg Revenue beat(2)-4.41%
Min Revenue beat(2)-6.3%
Max Revenue beat(2)-2.53%
Revenue beat(4)0
Avg Revenue beat(4)-3.07%
Min Revenue beat(4)-6.3%
Max Revenue beat(4)-1.26%
Revenue beat(8)4
Avg Revenue beat(8)0.64%
Revenue beat(12)8
Avg Revenue beat(12)2.65%
Revenue beat(16)12
Avg Revenue beat(16)4.55%
PT rev (1m)-22.58%
PT rev (3m)-64.14%
EPS NQ rev (1m)-13.97%
EPS NQ rev (3m)-207.1%
EPS NY rev (1m)-38.48%
EPS NY rev (3m)-85.12%
Revenue NQ rev (1m)-23.94%
Revenue NQ rev (3m)-46.12%
Revenue NY rev (1m)-22.09%
Revenue NY rev (3m)-25.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.51
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB 1.33
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS3.59
BVpS6.79
TBVpS6.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.44%
ROE -11.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.12%
FCFM N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 125.95%
Cap/Sales 2.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.93
Quick Ratio 12.7
Altman-Z 5.49
F-Score5
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)107.67%
Cap/Depr(5y)87%
Cap/Sales(3y)4.72%
Cap/Sales(5y)8.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-81.25%
EPS Next Y-74.25%
EPS Next 2Y-28.33%
EPS Next 3Y-14.72%
EPS Next 5Y6.61%
Revenue 1Y (TTM)27.68%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%-3.58%
Revenue Next Year-10.36%
Revenue Next 2Y-2.2%
Revenue Next 3Y2.02%
Revenue Next 5Y2.5%
EBIT growth 1Y-0.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.85%
EBIT Next 3Y7.61%
EBIT Next 5YN/A
FCF growth 1Y63.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.06%
OCF growth 3YN/A
OCF growth 5YN/A